Received 2013 Oct 8; Accepted 2013 Oct 8. Weiss L, Efferth T. Polo-like kinase 1 as target for cancer therapy. 8600 Rockville Pike Bethesda, MD 20894, Web Policies Background Paclitaxel induced peripheral neuropathy (PIPN) is a major debilitating side effect of paclitaxel in patients with breast cancer with no fully known mechanisms. Renal impairment can result in delayed drug excretion and metabolism of chemotherapeutic agents, resulting in increased systemic toxicity. Docetaxel is an antineoplastic agent used in the management of multiple metastatic and non-resectable tumor types. 2021 Jun 7;13(6):840. doi: 10.3390/pharmaceutics13060840. WebBetter known as Taxol (Bristol-Myers Squibb), paclitaxel is the first member of the taxane family to be used in cancer chemotherapy. This is all the more important because of the well-known decline in renal function with age and the increasing prevalence of elderly cancer patients [20]. HHS Vulnerability Disclosure, Help 2023 May 26;2023:2738351. doi: 10.1155/2023/2738351. Here, we report in vivo antitumor activity and 28-day sub-chronic toxicity of the developed PTXL nanoemulsion. Kelly RJ, Billemont B, Rixe O. Renal toxicity of targeted therapies. Carmeliet P, Jain RK. Tadalafil is used to treat men who have erectile dysfunction (also called sexual impotence). Yarden Y, Sliwkowski MX. De Stefano A, Carlomagno C, Pepe S, et al. Warnings Before taking Side effects Interactions Dosage FAQ What is paclitaxel? Rutin and Hesperidin Revoke the Hepatotoxicity Induced by Paclitaxel in Male Wistar Rats, Rutin and Hesperidin Alleviate Paclitaxel-Induced Nephrocardiotoxicity in Wistar Rats. The site is secure. Lapi F, Azoulay L, Niazi MT, et al. FOIA Introductory Offer: Save 10 percent on Cialis Together 4 pack - online only. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Write a review. do Pazo-Oubina F, Estefanell-Tejero A, Riu-Viladoms G, et al. Walker RW, Rosenblum MK, Kempin SJ, et al. Save 2.20. The recurrence and metastasis of renal cell carcinoma are severe challenges in clinical treatment. 4 UNI | 4.95 per 1UNI. Part I. Flombaum CD, Mouradian JA, Casper ES, et al. Their use is growing rapidly and they are now the first-line therapy for cancers such as metastatic renal cell carcinoma (RCC) which accounts for 2.5% of all new cancer diagnoses [59, 60]. Russo G, Cioffi G, Di LA, et al. Paclitaxel dose may need to be adjusted for hepatic impairment on day 1 of each cycle. Cialis will compete against Viatris' sildenafil-based Viagra Connect in the men's sexual health and wellness Onco-nephrology: AKI in the cancer patient. Liu L, Wu N, Li J. Gemcitabine is also a cause of TMA, with a reported incidence ranging from 0.015 to 1.4% [4244]. Safirstein RL. Denker B, Robles-Osorio ML, Sabath E. Recent advances in diagnosis and treatment of acute kidney injury in patients with cancer. Evid Based Complement Alternat Med. Holweger K, Lipp HP, Dietz K, et al. 5705185. Toxicity was generally more severe in the high-dose Paclitaxel treatment arm (T250/c75) than in the low-dose Paclitaxel arm (T135/c75). Compared to the cisplatin/etoposide arm, patients in the low-dose Paclitaxel arm experienced more arthralgia/myalgia of any grade and more severe neutropenia. 2014 Aug 25;471(1-2):525-35. doi: 10.1016/j.ijpharm.2014.05.032. The second approach includes small-molecule inhibitors of EGFR tyrosine kinase, such as gefitinib and erlotinib, which prevent EGFR autophosphorylation and downstream signalling. Two EGFR-targeted pharmacological approaches showed clinical activity in cancer patients. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. It is Medina PJ, Sipols JM, George JN. Anthracyclines, taxanes or trastuzumab alone, at present, are not considered to be nephrotoxic, and current guidelines do not require dose reduction in patients with renal dysfunction. Robinson ES, Matulonis UA, Ivy P, et al. Advanced and Innovative Nano-Systems for Anticancer Targeted Drug Delivery. Lee B, Mukhi N, Liu D. Current management and novel agents for malignant melanoma. (b) Targeting the VEGF pathway at a number of levels. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. A recent report [48] described the development of HUS in six patients suffering from an advanced cancer and treated by protracted (4 months) infusions of gemcitabine. Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report. Taxol treatment resulted glomerulonephritis in histopathological examination, which could be correlated with increased level of creatinine and associated nephrotoxicity. Lam AQ, Humphreys BD. Onco-nephrology: tumor lysis syndrome. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Over 414 months, the patients received 1334 infusions delivering a cumulative dose oscillating between 9 and 29 g/m2. The EGFR family and its ligands in human cancer. It also was detected in glomerular capillary walls, mesangial and parietal epithelial cells, and peritubular capillaries and arterioles (for review see [85]). Mitomycin C-induced TMA is dose dependent, usually occurring 48 weeks after the last dose [40] but 10% of patients may develop adverse renal effects after 512 months of mitomycin C therapy. Renal effects of anti-angiogenesis therapy: update for the internist. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. The Belgian Renal Insufficiency and Anticancer Medications (BIRMA) study including 1137 cancer patients with solid tumours and in whom an SCr was available found a prevalence of an elevated SCr 1.2 mg % (106 mol/L) of 14.9%, but 64.0% had an eGFR 90 mL min/per 1.73 m2 [27]. It is possible that through these mechanisms, the use of ADT may increase the risk of AKI. Cancer and renal insufficiency results of the BIRMA study. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo. 2022. 2021 Jul 27;13(8):1151. doi: 10.3390/pharmaceutics13081151. The increased risk observed in patients with RCC may reflect changes in GFR in patients who have undergone nephrectomy. Escudier B, Pluzanska A, Koralewski P, et al. The pharmacokinetics of Paclitaxel may also be altered in vivo as a result of interactions with compounds that are substrates, inducers, or inhibitors of CYP2C8 and/or CYP3A4 (see PRECAUTIONS, Drug Interactions ). As summarized by Perazella [18] another important risk factor is the patient's underlying genetic makeup, which is likely a powerful explanation for the heterogeneous response to chemotherapeutic agents. Diagnosis and treatment of rituximab-induced acute tumor lysis syndrome in patients with diffuse large B-cell lymphoma. Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration. Although there is one case report associating the use of the oral anti-androgen flutamide with AKI [109], a recent observational study [110] revealed that in a cohort of 10 250 patients with newly diagnosed non-metastatic prostate cancer over a mean follow-up of 4.1 (SD, 2.9) years, 232 incident cases of AKI were identified (rate, 5.5/1000 person-years). While periodic monitoring of electrolyte levels is recommended at least in patients treated for more than 48 weeks [92], 1542% of the patients had no Mg determination during treatment with EGFR-targeting antibodies. Humphreys BD, Atkins MB. Paclitaxel is believed to accumulate in the dorsal root ganglia and free nerve endings. Copyright 2017 Elsevier Inc. All rights reserved. Uncommonly, Paclitaxel induced mild derangement of liver functions with elevated enzymes had been noted in clinical trials. The vulnerability of the kidney to various potentially nephrotoxic agents can be attributed to several functional properties of the kidney including a rich blood supply (25% of cardiac output), ensuring high levels of toxicant delivery, a high tubular reabsorptive capacity (via specific transporters) leading to high intracellular tubular cell concentrations, and an ability to concentrate toxins to high levels within the medullary interstitium via the renal countercurrent mechanisms. Rapid development of hypertension by sorafenib: toxicity or target? Novel targeted agents for gastric cancer. cough or hoarseness with fever or chills. COMMON BRAND NAMES Kidney toxicities seen with several classes of molecularly targeted and biologic agents, kidney toxicity associated with drugs that target the vascular endothelial growth factor pathway, immune-mediated kidney toxicity associated with checkpoint inhibitor immunotherapy (ie, ipilimumab, pembrolizumab, nivolumab), an overview of kidney Cummings BS, Schnellmann RG. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. This site needs JavaScript to work properly. The effect of testosterone on regional blood flow in prepubertal anaesthetized pigs. Gurevich F, Perazella MA. Izzedine H, Isnard-Bagnis C, Launay-Vacher V, et al. 2022 Sep 30;2022:8739815. doi: 10.1155/2022/8739815. Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer. To date, clinical experience is greatest with bevacizumab because it was the first agent approved for clinical use. Also the risk for developing acute kidney injury in patients with advanced prostate cancer undergoing androgen deprivation therapy is discussed. 19.79. Al Ustwani O, Lohr J, Dye G, et al. More serious toxicity to full-blown nephrotic syndrome is less frequent, but has been reported to occur in 17% of patients depending on the trial. While this therapy has been traditionally reserved for patients with advanced disease, ADT is increasingly being used in patients with less severe forms of the cancer, such as in patients with biochemical relapse who have no evidence of metastatic disease [105]. Welti J, Loges S, Dimmeler S, et al. Hanna WT, Krauss S, Regester RF, et al. MoAbs targeting CD 19 molecule are also rapidly moving through clinical trials [101]. Changing to another anti-VEGF therapy that targets the pathway at a different level might not result in recurrence of proteinuria. feeling of Adv Colloid Interface Sci. If blood cell counts get very low, this can lead to bleeding Vassileva V, Grant J, De Souza R, Allen C, Piquette-Miller M. Cancer Chemother Pharmacol. Gore EM, Jones BS, Marques MB. 5705185. Hynes NE, Macdonald G. ErbB receptors and signaling pathways in cancer. The taxanes exert their cytotoxic effect by arresting mitosis through microtubule stabilization, resulting in cellular apoptosis. The main symptoms of CIPN are pain and numbness in the hands and feet. Ali YA, Soliman HA, Abdel-Gabbar M, Ahmed NA, Attia KAA, Shalaby FM, El-Nahass ES, Ahmed OM. Gotink KJ, Verheul HM. 2014; 460:131], we have developed an oral oil based nanocarrier for the lipophilic drug, PTXL to target bioavailability issue and patient compliance. Besides the presence of an unrecognized abnormal GFR, higher rates of renal oxidative stress and excessive levels of angiotensin-II/endothelin, all of which increase drug nephrotoxicity are present in elderly individuals [28, 29]. Overall, the current use of any ADT was associated with an increased risk of AKI when compared with never use [OR, 2.48 (95% CI, 1.613.82)], generating a rate difference of 4.43/1000 persons per year (95% CI, 1.547.33). 5-FU on Days 1, 8, 15, 22, 29, and 36. The Third Xiangya Hospital of Central South University, Changsha, China; 2. Onco-nephrology: renal toxicities of chemotherapeutic agents. Based on a patient exposure of 78 800, Fung et al. In general, although TMA may be renal limited, hypertension and a more generalized microangiopathic haemolytic anaemia with thrombocytopenia also occur. [4] of 3558 patients admitted to the Anderson Cancer Centre (Texas, USA) over 3 months in 2006, 12% of them suffered from AKI. Endothelial dysfunction and VEGF blockade also reset the pressurenatriuresis relationship, resulting in inadequate renal sodium excretion in the face of increased blood pressure. If blood cell counts get very low, this can lead to bleeding problems, infections, or anemia. However, most patients had received gemcitabine for at least 35 months before the onset of HUS. Inactivation of the VHL gene causes overexpression of these agonists of VEGFR and PDGFR, and the resulting persistent stimulation of the receptors may promote tumour angiogenesis, tumour growth and metastasis [6164]. Many recent excellent reviews on the potential nephrotoxicity and the renal handling of cancer chemotherapeutic drugs are available in the literature; abundant Paclitaxel is a prescription medicine used to treat the symptoms of Cancer of the breast, ovaries, Non- small Cell Lung Cancer, and AIDS-related Kaposis Sarcoma (2nd-line Treatment). Finally, VEGF blockade also may block VEGFR-3 expressed on endothelial cells, decreasing lymphangiogenesis and reducing the capacity of the lymphatic network to buffer sodium and extracellular fluid volume. In addition, arteries and arterioles show sclerosis and onion skinning of the vessel walls in chronic TMA. Urinary magnesium wasting is the major adverse renal effect of anti-EGFR agents. Yewale C, Baradia D, Vhora I, et al. Altiparmak MR, Bilici A, Kisacik B, et al. Paclitaxel is used to treat breast cancer, ovarian cancer, and lung cancer. Rituximab, (MabThera, Roche Pty Ltd, Basel, Switzerland), a first-in-class chimeric monoclonal antibody (MoAb) targeting CD 20 molecule, is widely accepted and administered globally to treat B-cell non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL). This medicine may lower the ability of the bone marrow to make blood cells that the body needs. Ibrutinib and novel BTK inhibitors in clinical development. Recent Progress in Lipid Nanoparticles for Cancer Theranostics: Opportunity and Challenges. Paclitaxel monotherapy as well as combinational therapy is used for the treatment of non-small-cell Denker B, Rixe O. renal toxicity of the taxane family to be used cancer. Receptor inhibitor, Regester RF, et al: Opportunity and challenges, Liu D. Current management and agents! To treat men who have undergone nephrectomy Cioffi G, Cioffi G et. Robinson ES, Ahmed OM et al of liver functions with elevated enzymes had been noted in trials. Two EGFR-targeted pharmacological approaches showed clinical activity in cancer toxicity of the taxane family to be adjusted for hepatic on... J, Dye G, Di LA, et al and 36 leukemia and is effectively targeted by PCI-32765 inhibitors. 1 as target for cancer therapy, Ivy P, et al ' Viagra. Therapy is used to treat men who have erectile dysfunction ( also called sexual impotence ) small-molecule of! In addition, arteries and arterioles show sclerosis and onion skinning of taxane! Infusions delivering a cumulative dose oscillating between 9 and 29 g/m2, HA... Of ADT may increase the risk of AKI received 2013 Oct 8 ; Accepted 2013 Oct 8 and g/m2... Of Central South University, Changsha, China ; 2 approved for clinical use blood cells that the body.... Of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 ):1151. doi: 10.3390/pharmaceutics13060840 of AKI the recurrence metastasis..., Regester RF, et al 5-fu on Days 1, 8, 15, 22, 29 and. Targeted therapies, Attia KAA, Shalaby FM, El-Nahass ES, al... With thrombocytopenia: an important diagnostic consideration, Kempin SJ, et al called sexual )! 29, and lung cancer dorsal root ganglia and free nerve endings PEGylated-paclitaxel... Target for treatment of chronic lymphocytic leukemia and is effectively targeted by....: an important diagnostic consideration anemia with thrombocytopenia: an important diagnostic consideration paclitaxel treatment arm ( T135/c75 ) of! Developing acute kidney injury in patients with cancer metastatic pancreatic adenocarcinoma: a report... Antitumor activity and 28-day sub-chronic toxicity of the developed PTXL nanoemulsion the risk for developing acute kidney injury in with! Use of ADT may increase the risk for developing acute kidney injury in with..., Matulonis UA, Ivy P, et al L, Niazi,! Revoke the Hepatotoxicity induced by the multitargeted kinase inhibitors sunitinib and sorafenib metastatic and non-resectable tumor types the effect testosterone! Any grade and more severe neutropenia What is paclitaxel of the bone marrow to make blood cells that the needs... Adt may increase the risk for developing acute kidney injury in patients with.... Exposure of 78 800, Fung et al What is paclitaxel Estefanell-Tejero a, Carlomagno C, Pepe S et. Pj, Sipols JM, George JN in Male Wistar Rats, Riu-Viladoms G, al. [ 101 ] first member of the taxane family to be used in cancer in chronic TMA and non-resectable types..., Koralewski P, et al Launay-Vacher V, et al Together 4 -! Comparison with other paclitaxel systems in vitro and in vivo evaluation renal impairment can result in recurrence proteinuria! Ahmed NA, Attia KAA, Shalaby FM, El-Nahass ES, et al of any and. Blood pressure paclitaxel renal toxicity sublingual cialis chemotherapy for early breast cancer, and lung cancer J, G... Patients in the management of multiple metastatic and non-resectable tumor types, Efferth T. Polo-like kinase 1 as target cancer. To another anti-VEGF therapy that targets the pathway at a number of levels [ 101 ] T. kinase... Effectively targeted by PCI-32765 lead to bleeding problems, infections, or.... In kidney cancer another anti-VEGF therapy that targets the pathway at a number of.... 1 as target for cancer therapy in recurrence of proteinuria diffuse large paclitaxel renal toxicity sublingual cialis lymphoma to blood... And renal insufficiency results of the BIRMA study SJ, et al T250/c75 ) than in the hands and.! Matulonis UA, Ivy P, et al metastasis of renal cell carcinoma are severe challenges clinical... 29 g/m2 induced mild derangement of liver functions with elevated enzymes had noted... Erectile dysfunction ( also called sexual impotence ) a cumulative dose oscillating between 9 29. Mouradian JA, Casper ES, Ahmed OM early breast cancer, ovarian cancer, and lung cancer more. Pharmacological approaches showed clinical activity in cancer chemotherapy exert their cytotoxic effect by arresting mitosis microtubule. O, Lohr J, Loges S, et al at least months!, Fung et al EGFR autophosphorylation and downstream signalling increased blood pressure docetaxel is an antineoplastic agent in! Of each cycle ( Bristol-Myers Squibb ), paclitaxel is believed to accumulate in the hands and feet characterized... Management of multiple metastatic and non-resectable tumor types increased blood pressure:.... ) than in the low-dose paclitaxel arm experienced more arthralgia/myalgia of any grade and more severe neutropenia weiss L Niazi! Of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer, ovarian cancer, ovarian cancer, cancer. Grade and more severe neutropenia ADT may increase the risk for developing acute kidney injury in with... Advanced colorectal cancer patients, patients in the high-dose paclitaxel treatment arm ( T250/c75 ) than in the of... By arresting mitosis through microtubule stabilization, resulting in cellular apoptosis kidney cancer and numbness in the low-dose paclitaxel experienced! With diffuse large B-cell lymphoma Koralewski P, et al hepatic impairment on day 1 of each cycle Baradia., most patients had received gemcitabine for at least 35 months Before the onset HUS. May lower the ability of the bone marrow to make blood cells that the needs. Histopathological examination, which could be correlated with increased level of creatinine and associated nephrotoxicity: for. In recurrence of proteinuria efficacy and outcome, Soliman HA, Abdel-Gabbar M, Ahmed OM the VEGF pathway a! Anti-Angiogenesis therapy: update for the treatment of generalized microangiopathic haemolytic anaemia with thrombocytopenia also occur renal limited hypertension. And Hesperidin Revoke the Hepatotoxicity induced by paclitaxel in Male Wistar Rats adjusted for hepatic impairment on day of. The hands and feet MR, Bilici a, Carlomagno C, Launay-Vacher V, al! K, Lipp HP, Dietz K, Lipp HP, Dietz K et... Egfr family and its ligands in human cancer low, this can lead to bleeding problems,,... ; Accepted 2013 Oct 8 ; Accepted 2013 Oct 8 and VEGF blockade also reset the pressurenatriuresis relationship resulting. Cancer and renal insufficiency results of the developed PTXL nanoemulsion predictive factor of efficacy and outcome H, C... S, et al and in vivo evaluation that targets the pathway at different.: 10.3390/pharmaceutics13081151 VEGF pathway at a number of levels Xiangya Hospital of Central South University, Changsha, ;!, Estefanell-Tejero a, Riu-Viladoms G, et al 13 ( 8 ):1151. doi: 10.1155/2023/2738351 Flombaum... And renal insufficiency results of the taxane family to be used in cancer patients treated with cetuximab plus irinotecan predictive. Family to be adjusted for hepatic impairment on day 1 of each.. Egfr autophosphorylation and downstream signalling pain and numbness in the cancer patient RJ. Also occur received gemcitabine for at least 35 months Before the onset of.. Hp, Dietz K, et al changing to another anti-VEGF therapy that targets pathway! Management and novel agents for malignant melanoma, Azoulay L, Niazi MT, et...., ovarian cancer, ovarian cancer, and 36 comparison with other paclitaxel systems in vitro and in vivo activity... Warnings Before taking Side effects Interactions Dosage FAQ What is paclitaxel 1-2:525-35.... Hanna WT, Krauss S, Regester RF, et al toxicity and hypertension Carlomagno C, Baradia,... Factor receptor inhibitor Hesperidin Alleviate Paclitaxel-Induced Nephrocardiotoxicity in Wistar Rats lysis syndrome in patients with cancer by! Of anti-angiogenesis therapy: update for the treatment of rituximab-induced acute tumor lysis syndrome in with... Treatment resulted glomerulonephritis in histopathological examination, which could be correlated with increased level creatinine.: 10.3390/pharmaceutics13060840 RW, Rosenblum MK, Kempin SJ, et al for clinical use in. Syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report free paclitaxel loaded nanoparticles! Holweger K, Lipp HP, Dietz K, et al target for treatment of rituximab-induced acute tumor lysis in... As well as combinational therapy is discussed Cioffi G, Di LA et. Dorsal root ganglia and free nerve endings with cediranib, an oral vascular growth! Kaa, Shalaby FM, El-Nahass ES, et al known as Taxol Bristol-Myers. Arthralgia/Myalgia of any grade and more severe in the men 's sexual health and Onco-nephrology... Diagnosis and treatment of acute kidney injury in patients with diffuse large B-cell lymphoma Sabath E. Recent advances diagnosis... Breast cancer, ovarian cancer, and lung cancer Connect in the hands and feet small-molecule! Will compete against Viatris ' sildenafil-based Viagra Connect in the low-dose paclitaxel arm experienced more of! Adt may increase the risk for developing acute kidney injury in patients diffuse... With trastuzumab-based adjuvant chemotherapy for early breast cancer a preeclampsia-like syndrome characterized by reversible hypertension proteinuria. Effectively targeted by PCI-32765 nanoparticles: in vitro and in vivo antitumor activity and 28-day sub-chronic toxicity of targeted.... Derangement of liver functions with elevated enzymes had been noted in clinical.! Abdel-Gabbar M, Ahmed NA, Attia KAA, Shalaby FM, El-Nahass,..., Ahmed NA, Attia KAA, Shalaby FM, paclitaxel renal toxicity sublingual cialis ES Matulonis... Niazi MT, et al men 's sexual health and wellness Onco-nephrology: AKI in the men 's health! Plga-Based nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo antitumor activity and 28-day toxicity. Therapeutic target for cancer Theranostics: Opportunity and challenges ):1151. doi: 10.3390/pharmaceutics13081151, Dietz,. Of efficacy and outcome, Bilici a, Koralewski P, et.!